Abstract: This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical compositions comprising lactoferrin (e.g., naturally occurring lactoferrin, recombinant lactoferrin) which function as inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral entry into a subject (e.g., human subject). The invention further relates to methods of preventing, treating and/or ameliorating symptoms related to conditions caused by the SARS-CoV-2 virus (e.g., COVID-19), comprising administering to a subject (e.g., human subject) lactoferrin (e.g., naturally occurring lactoferrin, recombinant lactoferrin) (e.g., oral formulation of lactoferrin, intravenous (IV) formulation of lactoferrin) alone or with additional agents (e.g., remdesivir).